Niraparib (MK-4827) tosylate

Catalog No.S7625 Synonyms: Niraparib tosylate, MK 4827 tosylate

Niraparib (MK-4827) tosylate Chemical Structure

Molecular Weight(MW): 492.59

Niraparib (MK-4827) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM.

Size Price Stock Quantity  
USD 117 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 8 Publications

1 Customer Review

  • Berberine activates PARP1 in ovarian cancer cells. PAR synthesis is detected by immunofluorescence staining in A2780 and HO8910 treated with different concentration of berberine alone or in combination with niraparib (10 μM) for 48 h. Top: representative examples of immunofluorescence staining of PAR. Scale bar, 20 μm. Bottom: quantification of PAR level in A2780 and HO8910. Immunofluorescence intensities were quantified by ImageJ. *P<0.05, **P<0.01

    Cell Death & Disease, 2017, 8: e3070. Niraparib (MK-4827) tosylate purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Niraparib (MK-4827) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM.
Targets
PARP2 [3]
(Cell-free assay)		 PARP1 [3]
(Cell-free assay)
2.1 nM 3.8 nM
In vitro

Micromolar concentrations of niraparib radiosensitizes tumor cell lines derived from lung, breast, and prostate cancers independently of their p53 status but not cell lines derived from normal tissues. Niraparib also sensitizes tumor cells to H2O2 and converts H2O2-induced single strand breaks (SSBs) into DSBs during DNA replication[5].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa NGDnT4lRem:uaX\ldoF1cW:wIHHzd4F6 Moi4O{Bl[Xm| NGjQU|RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSlKFQUGgZYZ1\XJiNzDkZZl{KGK7IHPlcIwhfGm2ZYKtZox2\SCjc4PhfUwhS0N3ME2wMlg3KM7:TR?= NGfje4cyQTh5M{m4NS=>
MDA-MB-436 NIjCTllRem:uaX\ldoF1cW:wIHHzd4F6 MVi2JIRigXN? NIX5cGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12M{[gZ4VtdHNiZYjwdoV{e2mwZzDCVmNCOSB3M{m2JEshOUd-QTDteZRidnRiYX\0[ZIhPiCmYYnzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygR2M2OD1yLkCxPEDPxE1? NITwe5gyQTh5M{m4NS=>
Capan1 MnzYVJJwdGmoZYLheIlwdiCjc4PhfS=> NVXZb4cxOTNiZHH5dy=> Mn\ORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFYYDhclEh[2WubIOg[ZhxemW|c3nu[{BDWkODMjC2NVc1\GWuVDDteZRifGmxbjDhcoQhdG:|czDv[kB4cWymLYT5dIUh[WyuZXzlJIFnfGW{IEGzJIRigXNiYomgZ4VtdCC2aYTldk1jdHWnIHHzd4F6NCCFQ{WwQVAvODlizszN MWixPVg4Ozl6MR?=
Jurkat MlfvSpVv[3Srb36gZZN{[Xl? M{LyWlk3KGh? NV[5SYkyUW6qaXLpeIlwdiCxZjDQRXJROSCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIHPlcIwhfmmjYnnsbZR6KGGodHXyJFk3KGi{czDifUBOXFNiYYPzZZkhcW5icILld4Vv[2Vib3[gNVAxKHWPIH;mJJRmdW:8b3zvcYll\SxiRVO1NF0xNjJizszN Mlv2NlM5PTBzOUm=
SUM149PT MUfDfZRwfG:6aXPpeJkh[XO|YYm= NYr4T3Y5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1WPMUS5VHQh[2WubIOgZ4FzenmrbnegRnJESTFibYX0ZY51KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFUhfG9iNzDkZZl{KGK7IFPlcIxVcXSncj3CcJVmKGG|c3H5MEBESzVyPUCuNFI1KM7:TR?= NGTRcFYzPTd4MUC5Oi=>
SUM1315MO2 M4rrZmN6fG:2b4jpZ4l1gSCjc4PhfS=> NIf5UpZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXU1zM{G1UW8zKGOnbHzzJINienK7aX7nJGJTS0FzIH31eIFvfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkAyOiCmYYnzJIJ6KEOnbHzUbZRmei2EbIXlJIF{e2G7LDDDR|UxRTBwMEKg{txO MmLQNlU4PjFyOU[=
UWB1.289 NFTpSpFEgXSxdH;4bYNqfHliYYPzZZk> M4TJTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHVYSjFwMki5JINmdGy|IHX4dJJme3OrbnegRnJESTFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPSC2bzC3JIRigXNiYomgR4VtdFSrdHXyMWJtfWViYYPzZZktKEOFNUC9NE46PzVizszN M{nuWVI2PzZzMEm2
DoTc2-4510 NVzpOXNnS3m2b4TvfIlkcXS7IHHzd4F6 NEjkNZlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFd1SlMj20OVExKGOnbHzzJINienK7aX7nJGJTS0F{IH31eIFvfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA2KHSxIEeg[IF6eyCkeTDD[YxtXGm2ZYKtRox2\SCjc4PhfS=> NEPwUYczPTd4MUC5Oi=>
A549 NVzzNWlwS3m2b4TvfIlkcXS7IHHzd4F6 NFzLbmJEgXSxdH;4bYNqfHliYXfhbY5{fCC5aXzkJJR6eGViaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA2KHSxIEeg[IF6eyCkeTDD[YxtXGm2ZYKtRox2\SCjc4PhfS=> MXiyOVc3OTB7Nh?=
BT20 NFLxNWREgXSxdH;4bYNqfHliYYPzZZk> M4nzOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJVOjBiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgOUB1dyB5IHThfZMh[nliQ3XscHRqfGW{LVLseYUh[XO|YYm= NFzTXJUzPTd4MUC5Oi=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
c-PARP /c-caspase 3 / γ-H2AX; 

PubMed: 29158830     


Western Blot data testing protein expression after treatment with Olaparib, Niraparib, and Talazoparib on Brca1-deficient cell line in W0069 cells.

29158830
Immunofluorescence
Rad51 / Geminin; 

PubMed: 27614696     


Immunofluorescence microscopy of niraparib-treated PDX cells (PH039) and irradiated cells showing RAD51 foci (arrow) within geminin positive cells and lack of RAD51 foci formation in control cells. 

27614696
In vivo MK-4827 strongly enhances the effect of radiation on a variety of human tumor xenografts, both p53 wild type and p53 mutant. MK-4827 reduces PAR levels in tumors by 1 h after administration which persisted for up to 24 h[1]. In vivo treatment with MK-4827 and radiation prolonged survival (p<0.01) compared to single modalities. In vivo superiority of MK-4827 plus radiation is further documented by significant elevations of cleaved caspase-3 and γ-H2AX in tumors from the combination group compared to single modality cohorts[4].

Protocol

Cell Research:

[2]
- Collapse
  • Cell lines: V-C8 cells
  • Concentrations: 50 nM
  • Incubation Time: 24 h
  • Method:

    V-C8 (BRCA2-negative) Chinese hamster cells are treated with the PARP inhibitor MK-4827 for 24 h, washed and incubated in drug-free medium for 5-7 days until colonies formed.


    (Only for Reference)
Animal Research:

[1]
- Collapse
  • Animal Models: Female nude mice (Ncr Nu/Nu)
  • Formulation: Suspended in 0.5% Methocel in deionized water
  • Dosages: 25 or 50 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (198.94 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 492.59
Formula

C19H20N4O.C7H8O3S
CAS No. 1038915-73-9
Storage powder
in solvent
Synonyms Niraparib tosylate, MK 4827 tosylate

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

PARP Signaling Pathway Map

Related PARP Products

  • G007-LK New

    G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.

  • NU1025 New

    NU1025 is a potent PARP inhibitor with IC50 of 400 nM.

  • SCR7 New

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.

  • Olaparib (AZD2281, Ku-0059436)

    Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

    Features:A potent PARP inhibitor (currently in late stage clinical trials).

  • Veliparib (ABT-888)

    Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

    Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.

  • Rucaparib (AG-014699,PF-01367338) phosphate

    Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

    Features:The first PARP inhibitor used in clinical trials combined with temozolomide.

  • Talazoparib (BMN 673)

    Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

    Features:Most potent and selective PARPi reported thus far.

  • Iniparib (BSI-201)

    Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.

  • PJ34 HCl

    PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

    Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).

  • AG-14361

    AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

    Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.

Tags: buy Niraparib (MK-4827) tosylate | Niraparib (MK-4827) tosylate supplier | purchase Niraparib (MK-4827) tosylate | Niraparib (MK-4827) tosylate cost | Niraparib (MK-4827) tosylate manufacturer | order Niraparib (MK-4827) tosylate | Niraparib (MK-4827) tosylate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID